Clinical trial
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
NCT00085111 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00085111 |
|---|---|
| Title | Bevacizumab in Treating Young Patients With Refractory Solid Tumors |
| Official title | A Phase I Study of Bevacizumab in Refractory Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | bevacizumab |
| Enrollment | 24 |
| Start date | Dec 1, 2003 |
| Primary completion | Oct 1, 2005 |
| First posted | Jun 11, 2004 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: